

NCIC CLINICAL TRIALS GROUP

RADIATION FORUM

MEETING AGENDA

EATON CHELSEA HOTEL, TORONTO, ON

ROOM: WREN

FRIDAY, MAY 1ST, 2015 – 8:30 AM – 12:00 PM

CHAIR: M. MCKENZIE

SENIOR INVESTIGATOR: WENDY PARULEKAR

STUDY COORDINATOR: ALEXANDER MONTENEGRO

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To understand and address, through clinical and translational research, the disease burden associated with solid tumours and haematological malignancies treated with radiotherapy in Canada.
- To review recent developments in the understanding of molecular biology of cancers treated with radiotherapy.
- To update, review, and discuss recent results of clinical studies involving radiotherapy conducted by the NCIC Clinical Trials Group or national/international collaborators.
- To provide mentoring opportunities for investigators new to clinical trial research.
- To understand and apply new clinical trial methodologies in the field of clinical research.

8:30 am	Welcome	M. McKenzie
8:35 am	<u>NCIC CTG led trials</u>	
	Dexamethasone vs. placebo in the prophylaxis of radiation-induced pain flare following palliative radiotherapy for bone met. NCIC CTG SC.23	R. Wong
	HDR brachytherapy in intermediate risk CaP. NCIC CTG PR.15	E. Vigneault
8:55 am	<u>NCIC CTG Intergroup studies</u>	
	Radiation doses and fractionation schedules for DCIS of the breast. NCIC CTG MA.33	I. Olivotto
	Preoperative Chemoradiotherapy vs. Preoperative Chemotherapy for Resectable Gastric Cancer. NCIC CTG GA.1	J. Ringash / R. Wong
	Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases. NCIC CTG CEC.5	C. Chung

continued on next page ...

9:25 am	<u>Updates in NCIC CTG approved studies:</u>	
	Randomized study of single 8 Gy versus BSC for symptomatic primary or metastatic liver cancer. NCIC CTG HE.1	L. Dawson
	SBRT vs. conventional palliative radiotherapy for spinal metastases. NCIC CTG SC.24	A. Sahgal
	Concurrent dabrafenib and trametinib with stereotactic radiation in BRAF mutation–positive malignant melanoma and brain metastases. NCIC CTG IND.224	A. Sahgal
9:55 am	<u>Updates on previous discussed proposals</u>	
	Postoperative adjuvant IMRT following cystectomy for T3/pT4 urothelial bladder cancer. NRG-GU001	E. Winquist on behalf of L. Eapen
	Precision radiotherapy for oligometastatic NSCLC (PROMISE-NSCLC): a randomized phase II study.	P. Cheung
	Randomized phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localized, prostate cancer. ENZARAD (ANZUP)	T. Niazi/M. Stockler
	Randomized phase II trial for patients with p16 positive, non-smoking associated, locoregionally advanced oropharyngeal cancer. NRG-HN002	J. Waldron
10:35 am	Coffee Break	
10:45 am	<u>New Study proposals</u>	
	Accelerated chemo-radiotherapy with/without nimorazole in HPV/p16-ve squamous cell head and neck cancer. EORTC 1219/DAHANCA-29	J. Waldron
	Randomized phase II and phase III studies of individualized treatment for nasopharyngeal carcinoma based on biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA).	J. Waldron
	Research platform for studies of SABR in oligometastatic disease. Lung SBRT proposal.	R. Wong
	Metabolically adaptive dose escalation in locally advanced non-small cell lung cancer.	A. Sun
	A phase II randomized study comparing HDR vs LDR monotherapy in localized prostate cancer.	E. Vigneault
	PCS-7: a CRPC-oligomet SBRT trial.	T. Niazi
11:50 am	Activities of the Radiation Oncology Quality Assurance Committee.	A. Nichol/C. Field
12:00 pm	Meeting adjourned.	